Autopsy report · NCT05481775
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Cause of deathFunding or business
“Clincal decision based on previous results”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Conditions
- Locally Advanced Non-small Cell Lung Cancer; Efficacy and Safety
- Interventions
- Anlotinib; Chemotherapy; Radiotherapy; Immunotherapy
- Participants
- 0
- Sites
- 1
- Countries
- China
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.